- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00637494
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
May 4, 2017 updated by: Corcept Therapeutics
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant.
The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by antidepressant in reducing psychotic symptoms in patients with a diagnosis of psychotic depression.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
Up to 450 patients with psychotic depression will be randomly assigned to receive either mifepristone or matching placebo.
Patients will be assessed by the investigator or site staff during screening and on study days.
A single antidepressant selected from a list of approved drugs will be administered after the administration of investigational drug.
Adverse events, laboratory assessments, electrocardiograms, and physical examinations will be used to assess safety.
Study Type
Interventional
Enrollment (Actual)
292
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Woodland International Research Group, Inc.
-
Little Rock, Arkansas, United States, 72201
- K&S Professional Research Services, LLC
-
-
California
-
Anaheim, California, United States, 92804
- South Coast Clinical Trials, Inc
-
Downey, California, United States, 90241
- Diligent Clinical Trials
-
Escondido, California, United States, 92025
- Synergy Clinical Research Center
-
Garden Grove, California, United States, 92845
- Collaborative Neuroscience Network, Inc.
-
Oakland, California, United States, 94612
- Pacific Research Partners
-
Oceanside, California, United States, 92056
- North County Clinical Research
-
San Bernardino, California, United States, 92408
- Breakthrough Clinical Trials
-
San Diego, California, United States, 92123
- Sharp Mesa Vista Hospital
-
San Diego, California, United States, 92126
- Cnri, Llc
-
-
Florida
-
Aventura, Florida, United States, 33180
- Professional Clinical Research, Inc.
-
Gainesville, Florida, United States, 32606
- University of Florida
-
Hollywood, Florida, United States, 33021
- Segal Institute for Clinical Research
-
Kissimmee, Florida, United States, 34741
- Accurate Clinical Trials
-
Miami, Florida, United States, 33144
- AMB Research Center
-
Orlando, Florida, United States, 32810
- Lakeside Behavioral Health
-
Tampa, Florida, United States, 33613
- University of South Florida Dept of Psychiatry and Neurosciences
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Atlanta Center for Medical Research
-
-
Illinois
-
Hoffman Estates, Illinois, United States, 60169
- Alexian Brothers Center for Psychiatric Research
-
-
Mississippi
-
Flowood, Mississippi, United States, 39232
- Precise Research Centers
-
-
Missouri
-
Creve Coeur, Missouri, United States, 63141
- Millennium Psychiatric Associate
-
Saint Louis, Missouri, United States, 63128
- PsychCare Consultants Research
-
-
New Jersey
-
Marlton, New Jersey, United States, 08053
- CRI Lifetree
-
-
New York
-
Cedarhurst, New York, United States, 11516
- Neurobehavioral Research, Inc.
-
Glen Oaks, New York, United States, 11004
- The Zucker Hillside Hospital
-
-
North Carolina
-
Hope Mills, North Carolina, United States, 28348
- Inquest Clinical Group/ Global Research Associates
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Baptist Medical Center
-
-
Ohio
-
Dayton, Ohio, United States, 45417
- Midwest Clinical Research Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Oklahoma Clinical Research Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- Lehigh Center for Clinical Research
-
Philadelphia, Pennsylvania, United States, 19131
- Belmont Center For Comprehensive Treatment
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh Medical Center (UPMC)
-
-
South Carolina
-
Charleston, South Carolina, United States, 29405
- Carolina Clinical Trials, Inc.
-
-
Texas
-
Austin, Texas, United States, 78731
- FutureSearch Clinical Trials, L.P.
-
Dallas, Texas, United States, 75390
- University of Texas Southwestern Medical Center
-
Dallas, Texas, United States, 75243
- Pillar Clinical Research, LLC
-
DeSoto, Texas, United States, 75115
- InSite Clinical Research, LLC
-
Houston, Texas, United States, 77074
- Clinical Trial Network
-
Houston, Texas, United States, 77008
- Claghorn-Lesem Research Clinic
-
Houston, Texas, United States, 77074
- Fein-Jennings Clinic, Inc.
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Lifetree Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
22 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Have provided written consent to participate in the study prior to any study procedures and understand that they are free to withdraw from the study at any time. Patients must be able to read and understand the consent form, complete study-related procedures, and communicate with the study staff
- Have a DSM-IV TR diagnosis of Major Depressive Disorder with Psychotic Features (DSM-IV 296.24 or 296.34), and are clinically symptomatic with their illness
- Have pre-specified minimum scores on standardized psychiatric rating scales at baseline
- Have not been taking excluded medication for at least 7 days prior to randomization
- Have a negative pregnancy test
- If not postmenopausal for ≥ 2 years or surgically sterile (6 months post-surgery), must consent (patient or partner) to utilize two medically acceptable methods of contraception, one of which is a barrier method, throughout the entire study period and for 3 months after the study is completed
Exclusion Criteria:
- Have any primary psychiatric diagnosis other than psychotic depression.
- Have a major medical problem, which in the opinion of the investigator would place the patient at undue risk.
- Have undergone electroconvulsive therapy within 3 months prior to randomization
- Have had a hospitalization due to a suicide attempt within 45 days prior to randomization
- Are female and of childbearing age, and are unable or unwilling to use two medically acceptable methods of contraception during the study and for three months after study completion, one of which must be a barrier method
- Are female and are pregnant or lactating
- Are currently taking excluded medications
- Have used drugs of abuse within 30 days prior to screen, as per patient report and urine drug screen
- Have a history of active drug or alcohol abuse within 3 months or dependence within 6 months prior to screening
- Are in the opinion of the investigator at immediate risk of suicide, or at risk of harming others
- Have received investigational therapy (drug, vaccine, biological agent or device) within 6 months prior to randomization
- Have previously participated in a clinical trial of mifepristone
- Have a history of an allergic reaction to mifepristone
- Are in the investigator's opinion not appropriate for participation in the study or may not be capable of following the study schedule for any reason
- Are patients who are employees of the study unit or their family members, students who are working in the study unit, or family members of the investigator or Corcept Therapeutics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: 1
Mifepristone followed by an antidepressant
|
1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
Other Names:
|
PLACEBO_COMPARATOR: 2
Placebo followed by an antidepressant
|
Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Mifepristone vs. Placebo Treated Patients With at Least a 50% Reduction From Baseline in Brief Psychiatric Rating Scale-Positive Symptom Subscale (BPRS-PSS) at Days 7 and 56
Time Frame: 56 days
|
Response as measured by 50% reduction in psychosis at Days 7 and 56 was compared between the group administered placebo and the group administered mifepristone
|
56 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Mifepristone Treated Patients With Plasma Drug Concentrations Equal to or Above 1637 ng/mL vs. Placebo Treated Patients Who Achieve a ≤ 50% Reduction in BPRS-PSS at Days 7 and 56
Time Frame: 56 days
|
Response as measured by 50% reduction in psychosis at Days 7 and 56 was compared between the group administered placebo and the group who achieved a sufficiently high plasma level of mifepristone
|
56 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002 Sep 1;52(5):386-92. doi: 10.1016/s0006-3223(02)01432-4.
- Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001 Oct;21(5):516-21. doi: 10.1097/00004714-200110000-00009.
- Block TS, Kushner H, Kalin N, Nelson C, Belanoff J, Schatzberg A. Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. Biol Psychiatry. 2018 Jul 1;84(1):46-54. doi: 10.1016/j.biopsych.2018.01.008. Epub 2018 Jan 31.
- DeBattista C, Belanoff J, Glass S, Khan A, Horne RL, Blasey C, Carpenter LL, Alva G. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry. 2006 Dec 15;60(12):1343-9. doi: 10.1016/j.biopsych.2006.05.034. Epub 2006 Aug 4.
- Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006 Mar;31(3):628-36. doi: 10.1038/sj.npp.1300884.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2008
Primary Completion (ACTUAL)
June 1, 2014
Study Completion (ACTUAL)
June 1, 2014
Study Registration Dates
First Submitted
March 11, 2008
First Submitted That Met QC Criteria
March 12, 2008
First Posted (ESTIMATE)
March 18, 2008
Study Record Updates
Last Update Posted (ACTUAL)
June 5, 2017
Last Update Submitted That Met QC Criteria
May 4, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mood Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Depression
- Depressive Disorder
- Psychotic Disorders
- Mental Disorders
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Abortifacient Agents
- Luteolytic Agents
- Abortifacient Agents, Steroidal
- Contraceptives, Postcoital, Synthetic
- Contraceptives, Postcoital
- Menstruation-Inducing Agents
- Mifepristone
Other Study ID Numbers
- C-1073-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Chulalongkorn UniversityNational Research Council of Thailand; Thanyarak InstituteCompletedMethamphetamine-induced PsychosisThailand
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchRecruitingEarly PsychosisUnited States
-
Yale UniversityCompleted
-
University of TorontoUniversity of British Columbia; Centre for Addiction and Mental Health; Queen... and other collaboratorsNot yet recruitingPsychotic Disorders | Schizophrenia | Psychosis | Schizophrenia; Psychosis
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
State reference center for psychosocial careUniversity of ValenciaCompleted
Clinical Trials on mifepristone
-
Corcept TherapeuticsCompletedPsychotic Disorders | Major Depressive DisorderUnited States
-
BioPro Medical LtdCompletedUterine Fibroid | Vaginal Bleeding.Israel
-
Corcept TherapeuticsRecruitingDiabetes Mellitus, Type 2 | HypercortisolismUnited States
-
Hadassah Medical OrganizationCompleted
-
VGX Pharmaceuticals, LLCCompletedHIV InfectionsUnited States
-
Cairo UniversityUnknown
-
University of ManitobaManitoba HarvestCompletedDiabetes Prevention | Obesity PreventionCanada
-
Gynuity Health ProjectsCompletedInduced AbortionGeorgia, Vietnam
-
University Hospital Inselspital, BerneUnknownCesarean DeliverySwitzerland
-
Planned Parenthood League of MassachusettsRecruiting